Study Finds Low Oxygen Environment Helps Tumors Silence Critical Genes
News Jul 18, 2014
The findings, published in the journal Cell Reports, suggest that this gene silencing process could be interrupted to increase the chances that aggressive tumors will respond to treatment.
As cancer develops, it often outstrips its blood supply and receives less oxygen than normal tissue. This low-oxygen environment, called hypoxia, is associated with aggressive tumors of all types that are more likely to resist chemotherapy and radiation therapy and progress. The study, which used colon cancer tissue, found that hypoxia also triggers the silencing of a critical tumor-suppressing gene called MLH1, according to Peter M. Glazer, MD, PhD, the Robert H. Hunter Professor and chairman of therapeutic radiology, and professor of genetics at Yale.
The team also identified an enzyme, LSD1 (lysine specific demethylase), associated with MLH1 that could be a target to reverse or block the silencing process. Since LSDI is an enzyme, it is possible to target it with small molecules to inhibit its activity.
“We’ve long known that hypoxic tumors are associated with worse prognoses, but the idea that hypoxic tumors could silence genes was an unexpected finding,” Glazer said. “Now that we know how big a role hypoxia plays, we have a new and clinically-relevant path to explore in terms of circumventing this process. The next step is to determine how hypoxia affects other tumor-suppressing genes.”
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE
Missing Hormone Gene Linked to Incurable Prostate CancerNews
A study has shown that the loss of a subtype of the gene HSD17B4 can contribute to treatment-resistant prostate cancer.READ MORE